Sepsis in obstetric and gynecologic patients

Current Clinical Topics in Infectious Diseases

Volumn , Issue 19, 1999, Pages 60-82

  Faro, Sebastian ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL INFECTION; CLASSIFICATION; FEMALE; HOSPITALIZATION; HUMAN; MICROBIOLOGY; PATHOPHYSIOLOGY; PELVIC INFLAMMATORY DISEASE; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; SEPSIS; SEPTIC SHOCK;

FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PELVIC INFLAMMATORY DISEASE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 0032601650     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (128)

1. Bone RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 1991;114:332-333.
2. Fein AM, Duvivier R. Sepsis in pregnancy. Clin Chest Med. 1992;13:709-722.
3. Walraven GE, Mkanje RJ, van Roosmalen J, van Dongen PW, Dolmans WM. Assessment of maternal mortality in Tanzania. Br J Obstet Gynaecol 1994;101:414-417.
4. Laguardia KD, Rotholz MV, Belfort P. A 10-year review of maternal mortality in a municipal hospital in Rio de Janeiro: a cause for concern. Obstet Gynecol 1990;75:27-32.
5. Stubblefield PG, Grimes DA. Septic abortion. N Engl J Med 1994;331:310-314.
6. Pearlman MD, Faro S. Obstetric septic shock: a pathophysiologic basis for management. Clin Obstet Gynecol 1990;33:482-492.
7. 2 generating lactobacilli. J Infect Dis 1991;164:94-100.
8. Skarin A, Sylwan J. Vaginal lactobacilli inhibiting growth of Cardnerella vaginalis, Mobiluncus, and other bacterial species cultured from vaginal content of women with bacterial vaginosis. Acta Path Microbiol Immunol Scand 1986;94:399-403.
9. Redondo Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990;12:856-872.
10. Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993;169(pt 2); 450-454.
11. Whittenbury R. Hydrogen peroxide formation and catalase activity in lactic acid bacteria. J Microb 1964;34:13-26.
12. Lee W, Clark SL, Cotton DB, Gonik B, Phelan J, Faro S, Giebel R. Septic shock during pregnancy. Am J Obstct Gynecol 1988;159:410-416.
13. Faro S, Martens M, Hammill H, et al. Ticarcillin/clavulanic acid versus clindamycin and gentamicin in the treatment of post ccsarean endomctritis following antibiotic prophylaxis. Obstet Gynecol 1989;73:808-812.
14. Roberts S, Maccato ML, Faro S, Pinell P. The microbiology of postcesarean wound morbidity. Obstet Gynecol 1993;81:383-386.
15. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for post-cesarean endometritis. Obstet Gynccol 1990;75:52-58.
16. Soper DE, Mayhall CG, Dalton HP. Risk factors for intraamnionic infection: a prospective epidemiologic study. Am J Obstet Gynecol 1989;161:562-566.
17. Gibbs RS, Cassell GH, Davis, JK, St. Clair PJ. Further studies on genital mycoplasmas an intra-amniotic infection: blood cultures and serologic response. Am J Obstet Gynecol 1986:154:717-726.
18. McCormack WM, Lee YH, Lin JS, Rankin JS. Genital mycoplasmas in postpartum fever. J Infect Dis 1973;127:193-196.
19. Rosene K, Eschenbach DA, Tompkins LS, Kenny GE, Watkins H. Polymicrobial early postpartum endometritis with facultative and anaerobic bacteria, genital mycoplasmas, and C. trachomatis. Treatment with piperacillin or cefoxitin. J Infect Dis 1986;153: 1028-1037.
20. Eschenbach DA. Bacterial vaginosis: emphasis on upper genital tract complications. Obstet Gynecol Clin North Am 1989;16:593-610.
21. Faro S, Phillips LE, Martens MG. Perspectives on the bacteriology of postoperative obstetric-gynecologic infections. Am J Obstet Gynecol 1988;158(pt 2):717-721.
22. Faro S. Review of vaginitis. Infect Dis Obstet Gynecol 1993;1:153-161.
23. Soper DE. Bacterial vaginosis and postoperative infections. Am J Obstet Gynecol 1993;169(pt 2):467-469.
24. Amstey MS. Low morbidity in the surgical patient with group B streptococci. Obst Gynecol 1977;50:428-430.
25. Lin L, Song J, Kimber N, et. al. The role of bacterial vaginosis in infection after major gynecological surgery. (Submitted for publication)
26. Gibbs RS, Blanco JD, St. Clair PJ, Castaneda YS. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. J Infect Dis 1982;145:1-8.
27. Newton ER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol 1993;36:795-808.
28. Pinell P, Faro S, Roberts S, Le S, Maccato M, Hammill H. Intranterine pressure catheter in labor: associated microbiology. Infect Dis Obstet Gynecol 1993;1:60-64.
29. Gonik B, Shannon RL, Shawar R, Costner M, Seibel M. Why patients fail antibiotic prophylaxis at cesarean delivery: histologic evidence for incipient infection. Obstet Gynecol 1992;79:179-184.
30. Duff P. Pathophysiology and management of postcesarean endomyometritis. Obstet Gynecol 1986;67:269-276.
31. Smith L Jr, Dildy G, Faro S. Personal communication. 1992.
32. Ledger WJ, Norman M, Gee C, Lewis W. Bacteremia on an obstetric-gynecologic service. Am J Obstet Gynecol 1975; 121:205-212.
33. Faro S. The effect of Timentin in the treatment of female pelvic soft tissue infections. Pharmacotherapy 1991;11(pt 2):80s-83s.
34. Blanco JD, Gibbs RS, Castaneda YS. Bacteremia in obstetrics: clinical course. Obstet Gynecol 1981;58:621-625.
35. Bryan CS, Reynolds KL, Moore EE. Bacteremia in obstetrics and gynecology. Obstet Gynecol 1984;64:155-158.
36. Shisler S, Kenton K, Faro S. Personal communication. 1997.
37. Dinarello CA, Gelfand JA, Wolff SM. Anti-cytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829-1835.
38. Fisher CJ, Dhaiaut J-FA, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-1844.
39. Platzer C, Meisel CH, Vogt K, et al. Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Inf Immunol 1995;7:517-523.
40. Fukushima R, Alexander JW, Granotti L, Ogle CK. Isolated pulmonary infection acts as a source of systemic tumor necrosis factor. Crit Care Med 1994;22:114-120.
41. Ford HR, Hoffman RA, Wong EJ, et al. Characterization of wound cytokines in the sponge matrix model. Arch Surg 1989;124: 1422-1428.
42. Meduri GV, Kohler G, Meadley S, et al. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts a poor outcome. Chest 1995;108:1303-1314.
43. Sander DN, Semple J, Truscott D, et al. Stimulation of muscle protein degradation by murine and human epidermal cytokines. Relationship to thermal injury. J Invest Dermatol 1986;87:711-714.
44. Krupper TS, Deitch EA, Baker CC, Wong W. The human burn wound as a primary source of interleukin-1 activity. Surgery 1986;100:409-414.
45. Puren AJ, Feldman C, Savage N, et al. Pattern of cytokine expression in community acquired pneumonia. Chest 1995;105:1342-1349.
46. 2 following trauma-hemorrhage and resuscitation: down-regulation of inflammatory cytokine (TNF; IL-6) release. J Surg Res 1992;52:364-371.
47. Wang P, Ba ZF, Morrison MH, Ayala A, Chaudry IH. Mechanism of the beneficial effect of pentoxifylline on hepatocellular function after trauma hemorrhage and resuscitation. Surgery 1992;112:451-457.
48. Tracey KJ, Lowry SF, Cermai A. Cachetin/ TNF-alpha in septic shock and septic adult respiratory distress syndrome (editorial). Ann Rev Respir Dis 1988;138:1377-1379.
49. Abraham E, Winderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. JAMA 1995;273:934-941.
50. Lewis RA, Austen KF, Sokerman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human disease. N Engl J Med 1990;323:645-655.
51. Petrak RA, Balk RA, Bone RC. Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthesis inhibitors in the pathogenesis of multiple organ failure. Crit Care Clin 1989;5:303-314.
52. Sigurdsson CH, Christenson JT, Baderel-Raksky M, Sadek S. Inestinal platelet trapping after traumatic and septic shock. An early sign of sepsis and multi-organ failure in critically ill patients? JAMA 1992;20:458-467.
53. Cipolle MD, Pasquale MD, Cerra FB. Secondary organ dysfunction. From clinical perspectives to molecular mediators. Crit Care Clin 1993;9:261-298.
54. Rinaldo JE, Gorry M, Stieter R, et al. Effect of endotoxin-induced cell injury on 70-KD heat shock proteins in bovine lung endothelial cells. Am J Respir Cell Mol Biol 1990; 3:207-216.
55. Conger J, Weil J. Abnormal vascular function following ischemia-reperfusion. J Invest Med 1995;43:431-442.
56. Levi M, Ten Cate H, Vander Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975-979.
57. Gomez-Jimenez J, Salgado A, Mourella M, et al. Nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med 1995;23:253-258.
58. Miyauchi T, Tomobe Y, Shiba R, et al. Involvement of endothelin in the regulation of human vascular tonus. Circulation 1990;81:1874-1880.
59. Ten Cate H, Brandjes DPM, Wolters HJ, Can Deventer SJH. Disseminated intravascular coagulation: pathophysiology, diagnosis, and treatment. N Horizons 1993;1:312-313.
60. Vander Poll T, Levi M, van Deventer JH. Coagulopathy: disseminated intravascular coagulation. In: Fein AM, Abraham EM, Balk RA, Bernard GR, Bone RC, Danzker DR, Fink MP, eds. Sepsis and multiorgan failure. Baltimore: Williams and Wilkins, 1997:255: 265.
61. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987;235:1348-1352.
62. Taylor FB Jr, Chang A, Fenell G, et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78:357-363.
63. Randow F, Syrke U, Meisel C, et al. Mechanisms of endotoxin desensitization: involvement of interleukin-10 and transforming growth factor-β. J Exp Med 1995;181:1887-1892.
64. Docke WD, Syrbe V, Meinecke A, et al. Improvement of monocyte function - a new therapeutic approach? In: Reinhart K, Eyrich K, Sprung C, eds. Sepsis: current perspectives in pathophysiology and therapy. Berlin: Springer-Verlag, 1994;473-500.
65. Livingston DH, Appel SM, Welihausen SR, et al. Depressed Interferon - γ production and monocyte HLA-DR expression after severe injury. Arch Surg 1988;123:1309-1313.
66. Mills CD, Caldwell MD, Gann DS. Evidence of a plasma-mediated "window" of immunodeficiency in rats following trauma. J Clin Immunol 1989;9:139-150.
67. Cody CS, Dunn DL. Endotoxins in septic shock. In: Neugebauer E, Holaday J, eds. CRC handbook on mediators in septic shock. Boca Raton, FL: CRC Press, 1993:1-37.
68. Westphal O, Westphal U, Summer T. History of pyrogen research. In: Schlessinger D, ed. Microbiology 1977. New York: American Society of Microbiology, 1977:221.
69. Dahlberg PS, Dunn DL. Endotoxin and sepsis. In: Fein AM, Abraham EM, Balk RA, Bernard DR, Bone RC, Dantzker DR, Fink MP, eds. Sepsis and multiorgan failure. Baltimore: Williams and Wilkins, 1997:45-61.
70. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;274;172-177.
71. Taveira D, Silva AM, Kaulback HC, et al. Brief report: shock and multiple organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993;328:1457-1460.
72. Manthey CL, Vogel SN. The role of cytokines in host responses to endotoxin. Rev Med Microbiol 1992;3:72-79.
73. Leeson MC, Fujihara Y, Morrison DC. Evidence for lipopolysaccharide as the predominant proinflammatory mediator in supernatants of antibiotic-treated bacteria. Infect Immun 1994;62:4975-4980.
74. Rietschel ET, Brade L, Holst O, et al. Molecular structure of bacterial endotoxin in relation to bioactivity. In: Novotny A, Spitzer JJ, Ziegler EJ, eds. Endotoxin research series. Vol 1: Cellular and molecular aspects of endotoxin reactions. New York: Excerpta Medica, 1990:15-32.
75. Fink MP. Adoptive immunotherapy of gramnegative sepsis: use of monoclonal antibodies to lipopolysaccharide. Crit Care Med 1993; 21:532-539.
76. Colin BB. The differentiation of mononuclear phagocytes: morphology, cytochemistry, and biochemistry. J Exp Med 1965;121-153.
77. Vogel S, Marshall S, Rosenstreich D. Analysis of the effects of lipopolysaccharide on macrophages: differential phagocytic response of C3H/HeN and C3H/HeJ macrophages in vitro. Infect Immun 1979;25:328-336.
78. Nathan CF. Secretory products of macrophages. J Clin Invest 1987;79:319-326.
79. Morrison DC, Ryan JL. Endotoxin and disease mechanism. Ann Rev Med 1987;38: 417-432.
80. Beutler B, Milsack IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985;229:867-869.
81. Dunn DC. Use of novel therapeutic agents for the treatment of serious infection. Am J Surg 1993;166:449-455.
82. Ohlsson K, Bjork P, Bergenfeldt M, et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-552.
83. Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin-1 receptor antagonists in the treatment of patients with sepsis syndrome. JAMA 1994;271:1836-1843.
84. Hu H, Moller G. Lipopolysaccharide-stimulated events in B cell activation. Scand J Immunol 1994;40:221-227.
85. Richards ML, Katz DH. Regulation of the murine Fc epsilon RII (CD32) gene. Functional characterization of IL-4 enhancer element. J Immunol 1994;152:3453-3466.
86. Mattsby-Baltzer I, Alving C. Antibodies to lipid Ai occurrence in humans. Rev Infect Dis 1984;6:553-557.
87. Wilson M, Jones D, Munkinbeck P, Morrison D. Serum dependent and independent effects of bacterial lipopolysaccharides on human neutrophil oxidative capacity in vitro. J Reticuloendthel Soc 1982;31:43-57.
88. Moore KL, Andreoli SP, Esmon NL, et al. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987;79:124-130.
89. Arditi M, Zhou J, Dorio R, et al. Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14. Infect Immun 1993;221:339-349.
90. Biller TR. Nitric oxide: novel biology with clinical relevance. Ann Surg 1995:221:339-349.
91. Cooper N, Morrison D. Binding and activation of the first component of human complement of lipid A region of lipopolysaccharide. J Immunol 1978;120:1862-1868.
92. Salzman MB, Rubin LG. Intravenous catheter-related infections. In: Aronoff SC, Hughes WT, Kohl S, et al., eds. Advances in pediatric infectious diseases. Vol. 10. St. Louis: Mosby, 1995:337-368.
93. Rubin M, Palan L, Vivas JR, et al. Predominance of gram-positive micro-organisms as a cause of septicema in patients with hematological malignancies. Infect Control Hosp Epidemiol 1994;15:101-104.
94. Wenzel RP, Pinsky MR, Uleritch RJ, Young L. Current understanding of sepsis. Clin Infect Dis 1996;22:407-413.
95. Braun V, Focareta T. Pre-forming bacterial protein hemolysins. Crit Rev Microbiol 1991;18:115-158.
96. Berry AM, Alexander JE, Mitchell TJ, et al. Effect on defined point mutations in the pnenmolysin gene in the virulence of Streptococcus pneumonias. J Clin Invest 1995;95: 142-150.
97. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illness. Microbiol 1990;17:251-272.
98. Hinshaw LB, Emerson TE, Taylor FB. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J Trauma 1992;33:568-673.
99. Riesenfeld-Orn I, Wolpe S, Garcia-Bustos JF, et al. Production of interleukin-1 but not tumor necrosis factor by human monocytcs stimulated with pneumococcal cell surface components. Infect Immun 1989;57:1890-1893.
100. Bhakdi S, Klomisch T, Nuber P, Fischer W. Stimulation of monokine production by lipoteichoic acids. Infect Immun 1991;59: 4614-4620.
101. Standiford TJ, Arenberg DA, Danforth JM, et al. Lipoteichoic acid induces secretion of interleukin-8 from human blood monocytcs: a cellular and molecular analysis. Infect Immun 1994;62:119-125.
102. Hack CE, Hart M, Straik van Schindel RJM, et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992;60:2835-2842.
103. Cabellos C, MacIntyre DE, Forrest M, et al. Differing roles for platelet-activating factor during inflammation of the lung and subarachnoid space. J Clin Invest 1992;90:612-618.
104. Faro S. Group B, beta-hemolytic streptococci and puerperal infections. Am J Obstet Gynecol 1981;139:686-689.
105. James FM, Greiss FC, Kemp RA. An evaluation of vasoprcssor therapy for maternal hypotension during spinal anesthesia. Anesthesiology 1970;33:25-34.
106. Shnider SM, de Lorimier AA, Holl JW, et al. Vasopressors in obstetrics 1. Correction of fetal acidosis with ephedrinc during spinal hypotension. Am J Obstet Cynecol 1968;102:911-919.
107. Reimer LG, Relier LB. Gardnerella vaginalis bacteremia. A review of thirty cases. Obstet Gynecol 1984;64:170-174.
108. Shoemaker WC, Montgomery ES, Kaplan E, et al. Physiologic patterns in surviving and nonsurviving shock patients. Arch Surg 1973; 106:630-636.
109. Kaufman BS, Rackow EC, Falk JL. The relationship between oxygen delivery and consumption during fluid resuscitation of hypovolemic and septic shock. Chest 1954:85: 33-38.
110. Hawkins DF. Management and treatment of obstetric bacteremia shock. J Clin Pathol 1980;33:895-898.
111. Roberts JM, Laro SRK. Hemorrhagic and endotoxic shock: a pathophysiologic approach to diagnosis and management. Am J Obstet Gynecol 1971;110:1041-1045.
112. Swan HJ, Ganz W, Forrester J, et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 1970;283:447-451.
113. Shoemaker WC, Kram HB, Appel PL, et al. The efficacy of central venous and pulmonaryartery catheters and therapy based upon them in reducing mortality and morbidity. Arch Surg 1990;125:1332-1336.
114. Lindeborg DM, Pearl RG. Recent advances in critical care medicine: inotropic therapy in the critically ill patient. Int Anesthesiol Clin 199;31:49-54.
115. Pozembka DT. Cardiovascular abnormalities in sepsis. N Horizons 1993;2:324-326.
116. Rao PS, Cavanaugh D. Endotoxic shock in the primate: some effects of dopamine administration. Am J Obstet Gynecol 1982;144:61-65.
117. Goldberg LI. Dopamine: clinical uses of an endogenous catecholamine. N Engl J Med 1974;291:707-710.
118. Boollaert PE, Bauer P, Andibert G, et al. Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine-resistant septic shock. Chest 1990;98:949-953.
119. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993;103: 1826-1829.
120. Hinds C, Watson D. Manipulating hemodynamic and oxygen transport in critically ill patients. N Engl J Med 1995;33:1074-1077.
121. Altura BM, Gebrewold A, Burton RW. Failure of microscopic metarterioles to elicit vasodilator responses of acetylcholine, bradykinin, histamine, and substance P after ischemic shock, endothelial cells. Microcirc Endothelium Lymphatics 1985;2:121-126.
122. Knuppel RA, Papienei SR, Cavanaugh D. Septic shock in obstetrics. Clin Obstet Gynecol 1987;27:3-7.
123. Demling RH, Labonde C, Ikegami K. Physiologic support of the septic patients. Surg Clin North Am 1994;74;637-640.
124. Fiddian-Green RG, Haglund U, Gutierrez G, et al. Goals for the resuscitation of shock. Crit Care Med 1993;21:25-28.
125. Shoemaker WC, Appel PL, Kram HB. Role of oxygen debt in the development of organ failure sepsis, and death in high-risk surgical patients. Chest 1992;102:208-211.
126. Sugerman HJ, Peyton JWR, Greenfield LJ. Gram-negative sepsis. In: Thai A, ed. Current problems in surgery. Chicago: Year Book Medical Publishers, 1981.
127. McClean KL, Sheehan GJ, Harding GKM. Intra-abdominal infection: a review. Clin Infec Dis 1994;19:100-116.
128. Malangoni MA, Shumate CR, Thomas HA, Richardson JD. Factors influencing the treatment of intra-abdominal abscess. Am J Surg 1990;159:167-170.